Examining the Prevalence of Chagas Disease in the US


Recent findings on the prevalence of Chagas disease in California are in line with 2009 estimates from the Centers for Disease Control and Prevention.

Unlike with Zika virus, Chagas disease is hardly a new import from South America to the United States.

However, exactly how many people in United States are infected with the insect-borne parasitic disease remains unknown. Estimates published by researchers from the Centers for Disease Control and Prevention (CDC) in 2009 suggest that more than 300,000 Americans may have Chagas, but these figures are based on previously published seroprevalence figures, and their accuracy has been called into question, given that the bulk of diseases go undiagnosed.

A new study published on May 1, 2017 in the journal Clinical Infectious Diseases (CID) may provide researchers with a better sense of the scope of the Chagas problem in the United States, where the disease is not endemic. Indeed, through blood tests of a large sample of Latin America-born residents of Los Angeles County, California, the authors from the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center and the CDC’s Division of Parasitic Diseases and Malaria found an overall Chagas prevalence of 1.24%. This suggests that there may be as many as 30,000 cases of Chagas in Los Angeles County alone.

“I am a cardiologist, and what surprised me initially, before this study began, were the number of cases I was finding with unusual cardiomyopathy,” study co-author Sheba K. Meymandi, MD, Director of the Center of Excellence for Chagas Disease, told Contagion. “When we took a closer look, it turned out that many of the pathologies we were seeing could only be explained by Chagas disease, and when we tested our cardiology patients, we found very high rates. This made me realize it was important to look for evidence of the disease in the general population as well.”

Although Dr. Meymandi admits she and her colleagues were surprised at how prevalent the disease is in this particular region of Southern California, they do note that their final estimates are in line with the CDC’s 2009 findings, which pegged Chagas prevalence at 1.31%. What is different, however, is the methods by which the numbers were drawn. Over a 6-year period, Dr. Meymandi and her team screened blood samples from 4,755 Latin American-born LA County residents for serologic evidence of Chagas. They collected demographic data and assessed the impact of established risk factors for Chagas (including gender and country of origin) on diagnosis. They found that prevalence was highest among immigrants from El Salvador (3.45%), and confirmed previous studies that determined that living in homes made from adobe and/or mud and with thatched roofs increased risk for a Chagas diagnosis. Chagas was also more common among women in the study population.

“Awareness [of Chagas] right now is very low, not only for the public but among providers,” Dr. Meymandi said. “Right now, patients who get diagnosed after giving blood are not getting enough help from doctors, who are unfamiliar with treatment guidelines, and less than 0.2% of expected cases have received treatment, [which] is unacceptable.”

In a commentary published with Dr. Meymandi et al’s findings in CID, Jennifer Manne-Goehler, MD, DSC, Research Fellow, Harvard T.H. Chan School of Public Health, describes Chagas disease “as a bellwether for the present and future success of the US healthcare system in reaching medically underserved Latin American populations… The work of Meymandi and colleagues highlights that Chagas disease is a real and urgent health concern facing a highly neglected community among us. It is our duty to bring this epidemic of Chagas disease in the United States, and those affected by it, out of the shadows.”

Brian P. Dunleavy is a medical writer and editor based in New York. His work has appeared in numerous healthcare-related publications. He is the former editor of Infectious Disease Special Edition.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.